Loading...
XHKG
1312
Market cap22mUSD
May 29, Last price  
0.03HKD
1D
0.00%
1Q
6.67%
Jan 2017
-95.29%
IPO
-85.19%
Name

Kontafarma China Holdings Ltd

Chart & Performance

D1W1MN
P/E
—
P/S
0.20
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
-9.55%
Revenues
898m
+10.93%
451,444,000725,298,000704,698,000703,468,000733,125,000465,739,000633,279,0001,344,336,0002,093,724,0001,482,347,0001,009,134,000961,089,000894,062,000809,107,000897,521,000
Net income
-76m
L+161.89%
168,332,00076,158,00026,834,00032,564,00017,280,000-34,237,000-37,076,000-1,806,00032,499,00065,211,000-20,085,000-4,553,000-109,744,000-28,843,000-75,537,000
CFO
0k
-100.00%
115,805,000-7,609,00045,311,000-64,462,000-8,130,000-14,735,00012,432,000-47,262,00066,864,00025,670,000206,933,00075,068,000-2,165,00037,119,0000
Dividend
May 27, 20130.02 HKD/sh

Profile

Tongfang Kontafarma Holdings Limited, an investment holding company, engages in the manufacture and sale of prescription drugs and laboratory related products in Mainland China, Singapore, Taiwan, and the United States. The company operates in Pharmaceutical Business and Fitness Business segments. It also offers chemical drugs and prescribed traditional Chinese medicines; operates fitness centers; operates in the franchise business; and provides consultation services for fitness and health activities. The company trades in laboratory related products; researches and develops medical products; and offers corporate advisory services. As of December 31, 2021, it operated 12 fitness centers and 2 yoga center in Taiwan; and 10 fitness centers in Singapore. The company was formerly known as Allied Cement Holdings Limited and changed its name to Tongfang Kontafarma Holdings Limited in August 2016. The company was founded in 1993 and is headquartered in Wan Chai, Hong Kong. Tongfang Kontafarma Holdings Limited is a subsidiary of China Health Management Investment Limited.
URL
https://www.tfkf.com.hk/
IPO date
Jan 18, 2012
Employees
715
Domiciled in
HK
Incorporated in
KY

Valuation

Title
HKD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
897,521
10.93%
809,107
-9.50%
894,062
-6.97%
Cost of revenue
940,035
901,057
975,637
Unusual Expense (Income)
NOPBT
(42,514)
(91,950)
(81,575)
NOPBT Margin
Operating Taxes
1,042
17,196
(7,992)
Tax Rate
NOPAT
(43,556)
(109,146)
(73,583)
Net income
(75,537)
161.89%
(28,843)
-73.72%
(109,744)
2,310.37%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
150,507
105,680
222,580
Long-term debt
355,817
509,619
696,939
Deferred revenue
982
22,834
Other long-term liabilities
36,902
12,230
13,336
Net debt
415,739
527,640
734,121
Cash flow
Cash from operating activities
37,119
(2,165)
CAPEX
(23,923)
(51,679)
Cash from investing activities
144,143
121,531
Cash from financing activities
(198,812)
(137,332)
FCF
128,038
(38,713)
143,045
Balance
Cash
90,585
87,659
142,595
Long term investments
42,803
Excess cash
45,709
47,204
140,695
Stockholders' equity
(5,988)
39,980
119,340
Invested Capital
1,301,615
1,369,001
1,614,137
ROIC
ROCE
EV
Common stock shares outstanding
5,578,714
5,578,714
5,578,714
Price
0.03
-27.78%
0.04
-20.00%
0.05
-8.16%
Market cap
145,047
-27.78%
200,834
-20.00%
251,042
-8.16%
EV
543,621
733,131
1,522,491
EBITDA
(42,514)
15,214
49,170
EV/EBITDA
48.19
30.96
Interest
15,250
23,278
Interest/NOPBT